HAEHaemonetics Corporation

Haemonetics Corporation (NYSE: HAE) | Price: $118.04 | Today's Change: +16.06%

---

What Happened

Haemonetics filed an 8-K (Item 7.01 — Regulation FD Disclosure) with the SEC on October 8, 2026, disclosing its financial results for the first quarter of fiscal year 2027. The company reported revenue of $321.4 million, net income of $34.0 million, and diluted earnings per share of $0.70 for the quarter. Operating income came in at $53.9 million, underscoring that the business generated meaningful profit at the operating level on the quarter's top line.

---

Why It Matters

The share price has surged +16.06% on the day of this filing, a move that indicates the market found the Q1 FY2027 results materially stronger than what had been priced in. For investors, the key near-term facts are straightforward:

• Revenue of $321.4M for a single quarter represents a significant run-rate for a company whose FY2015 annual revenue was reported at $892.0M — illustrating the scale of growth the business has achieved over the intervening years.
• Net income of $34.0M and diluted EPS of $0.70 confirm that profitability is intact at the bottom line.
• Operating income of $53.9M suggests healthy conversion from revenue to operating profit, with the gap between operating and net income reflecting items below the operating line (financing costs, taxes, etc.) that are not broken out in the structured data provided from this filing.

The double-digit stock reaction implies that either the magnitude of the numbers, the trajectory they imply, or guidance language within the disclosure exceeded consensus expectations — though specific guidance figures are not available in the structured XBRL data provided.

---

Analysis

A 16% single-day move on an earnings disclosure is a notable signal that the street was positioned defensively heading into this print. The Q1 FY2027 results — $321.4M in revenue and $0.70 in diluted EPS — appear to have reset expectations upward. It is worth noting that StockWatch published its Initiating Coverage on Haemonetics on the same date as this filing, October 8, 2026; readers seeking a full fundamental framework for the stock should consult that report directly.

What to watch going forward:

• Revenue growth trajectory: Whether Q1's $321.4M pace is sustainable or represents seasonal or one-time strength.
• Operating margin sustainability: Operating income of $53.9M on $321.4M of revenue implies an operating margin of approximately 16.8% — a figure worth tracking in subsequent quarters.
• Below-the-line items: The spread between operating income ($53.9M) and net income ($34.0M) — roughly $19.8M — warrants attention in the full earnings release, as it likely reflects interest expense, tax provisions, or non-recurring charges.
• Management commentary: Item 7.01 filings typically accompany press releases or investor presentations; the tone and specificity of any forward-looking statements will be critical for understanding whether the market's re-rating proves durable.

---

Disclaimer

This report is a news and informational summary based solely on data from Haemonetics Corporation's SEC filing (Form 8-K, filed October 8, 2026) and publicly available stock price data. It does not constitute investment advice, a solicitation to buy or sell any security, or a complete analysis of the company's financial condition. No rating or price target is assigned or implied herein. Investors should conduct their own due diligence and consult a qualified financial adviser before making any investment decision.

Existing Coverage

StockWatch has full coverage on HAE, published 2026-10-08. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-10-08. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/313143/000031314326000138/hae-20261008.htm